SCHEMBL7726224

SCHEMBL7726224

CCOC(=O)c1cnc(CC)nc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.56
KDM4E B2RXH2 2/20 0.56
NFKB1 P19838 3/20 0.51
NFKB2 Q00653 3/20 0.51
RELA Q04206 3/20 0.51
FOS P01100 2/20 0.51
JUN P05412 2/20 0.51
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
HSP90AA1 P07900 1/20 0.47
MAPT P10636 4/20 0.45
HPGD P15428 1/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
RAB9A P51151 4/20 0.45
NPC1 O15118 3/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
LMNA P02545 1/20 0.45
MAPK1 P28482 1/20 0.45
ATM Q13315 1/20 0.45
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4139836 0.88 ALDH1A1 (0.54) ALDH1A1KDM4ENFKB1NFKB2RELA
SCHEMBL13447383 0.88 ALDH1A1 (0.54) ALDH1A1KDM4ENFKB1NFKB2RELA
SCHEMBL9589692 0.88 HSP90AA1 (0.55) ALDH1A1KDM4ENFKB1NFKB2RELA
SCHEMBL16682717 0.87 ALDH1A1 (0.53) ALDH1A1KDM4ENFKB1NFKB2RELA
SCHEMBL9589351 0.85 ALDH1A1 (0.52) ALDH1A1KDM4ENFKB1NFKB2RELA
SCHEMBL11098691 0.84 ALDH1A1 (0.56) ALDH1A1KDM4EKMT2AMEN1HSP90AA1
SCHEMBL9588606 0.84 ALDH1A1 (0.51) ALDH1A1KDM4ENFKB1NFKB2RELA
SCHEMBL427402 0.84 ALDH1A1 (0.63) ALDH1A1KDM4ENFKB1NFKB2RELA
SCHEMBL476310 0.84 ALDH1A1 (0.59) ALDH1A1KDM4ENFKB1KMT2AMEN1
SCHEMBL29922173 0.84 ALDH1A1 (0.59) ALDH1A1KDM4ENFKB1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160318933-A1 FUSED PYRAZOLE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2016-11-03 US disclosed
US-6391885-B1 CONTROLLING APOPTOSIS IN AUTOIMMUNE DISEASE CELL PATHWAYS, INC. 2002-05-21 US disclosed
US-6060477-A Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives CELL PATHWAYS, INC. (US) 2000-05-09 US disclosed
US-5250548-A Treating hypertension, heart failure ABBOTT LABORATORIES (US) 1993-10-05 US disclosed
EP-0351058-B1 PYRIMIDOPYRIMIDINE DERIVATIVES SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1993-06-02 EP disclosed
US-5162316-A Pyrimido[4,5-d]pyrimidine derivatives for use as bronchodilators SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1992-11-10 US disclosed
EP-0475206-A2 Angiotensin II receptor antagonists ABBOTT LABORATORIES (US) 1992-03-18 EP disclosed
EP-0351058-A1 Pyrimidopyrimidine derivatives SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1990-01-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160318933-A1 FUSED PYRAZOLE DERIVATIVE DRD4, DRD2, DRD3 ALDH1A1 330/4885KDM4E 1122/4885NFKB1 4538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.